Brief Psychotherapies for Emotional Disorders in Primary and Secondary Care
Brief Psychotherapies for Emotional Disorders in Primary and Secondary Care: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Córdoba
-
Cordoba, Córdoba, Spain, 14071
- Universidad de Córdoba
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Emotional Disorder
Exclusion Criteria:
- Severe mental disorder
- Substance use disorder
- Severe depression
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Brief Individual Psychotherapy
Individual brief psychological intervention by adaptation of the Guide NICE "Common Mental Health Disorders" (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010).
This intervention is provided by clinical psychologist in secondary care.
|
Time-limited transdiagnostic evidence-based psychological treatment
|
|
Experimental: Brief Group Psychotherapy
Group brief psychological intervention by adaptation of the Guide NICE "Common Mental Health Disorders" (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010).
This intervention is provided by clinical psychologist in primary care.
|
Time-limited transdiagnostic evidence-based psychological treatment
|
|
Active Comparator: Treatment as usual
Medication provided by a general practitioner.
|
Treatment as usual in PC
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patient Health Questionnaire (PHQ-15)
Time Frame: 10 weeks
|
The Patient Health Questionnaire-Somatoform Disorder is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders.The PHQ-15 is the somatization module, which scores each DSM-IV criteria as "0" (not bothered at all) to "2" (bothered a lot).
The more score the more severity.
|
10 weeks
|
|
State-Trait Anxiety Inventory (STAI)
Time Frame: 10 weeks
|
The State-Trait Anxiety Inventory is a commonly used measure of trait and state anxiety (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983).
It can be used in clinical settings to diagnose anxiety and to distinguish it from depressive syndromes.
It also is often used in research as an indicator of caregiver distress AnxietyForm Y, its most popular version, has 20 items for assessing trait anxiety and 20 for state anxiety.
All items are rated on a 4-point scale (e.g., from "Almost Never" to "Almost Always").
Higher scores indicate greater anxiety.
The STAI is appropriate for those who have at least a sixth-grade reading level.
Internal consistency coefficients for the scale have ranged from .86 to .95;
test-retest reliability coefficients have ranged from .65 to .75 over a 2-month interval (Spielberger et al., 1983).
|
10 weeks
|
|
Beck Depression Inventory (BDI-II)
Time Frame: 10 weeks
|
The Beck Depression Inventory (second edition) is a widely used 21-item self-report inventory measuring the severity of depression in adolescents and adults.
The BDI-II was revised in 1996 to be more consistent with DSM-IV criteria for depression.
For example, individuals are asked to respond to each question based on a two-week time period rather than the one-week timeframe on the BDI.
The BDI-II is widely used as an indicator of the severity of depression, but not as a diagnostic tool, and numerous studies provide evidence for its reliability and validity across different populations and cultural groups.
The more score the more depression severity.
|
10 weeks
|
|
Patient Health Questionnaire (PHQ-9)
Time Frame: 10 weeks
|
The Patient Health Questionnaire-Depression is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders.The PHQ-9 is the depression module, which scores each of the 9 DSM-IV criteria as "0" (not at all) to "3" (nearly every day).
The more score the more severity.
|
10 weeks
|
|
Patient Health Questionnaire (PHQ-PD)
Time Frame: 10 weeks
|
The Patient Health Questionnaire-Panic Disorder is a self-administered version of the PRIME-MD diagnostic instrument for common mental disorders.The PHQ-PD is the panic disorder module, which scores each DSM-IV criteria as "yes" or "no".
Higher scores mean greater severity of panic disorder.
|
10 weeks
|
|
Generalized Anxiety Disorder score (GAD-7)
Time Frame: 10 weeks
|
The Generalized Anxiety Disorder score is calculated by assigning scores of 0, 1, 2, and 3, to the response categories of 'not at all', 'several days', 'more than half the days', and 'nearly every day', respectively, and adding together the scores for the seven questions.
Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively.
When used as a screening tool, further evaluation is recommended when the score is 10 or greater.
Using the threshold score of 10, the GAD-7 has a sensitivity of 89% and a specificity of 82% for GAD.
|
10 weeks
|
|
Brief Symptom Inventory (BSI-18)
Time Frame: 10 weeks
|
The Brief Symptom Inventory contains the three six-item scales somatization, depression, and anxiety as well as the Global Severity Index (GSI), including all 18 items.
The BSI-18 is the latest and shortest of the multidimensional versions of the Symptom-Checklist 90-R.
The more score the more symptoms patients report.
|
10 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Brief-Psychotherapies
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.